key: cord-0714664-fvlh2gkf
authors: Gabrielle, Pierre-Henry; Baudin, Florian; Ben Ghezala, Ines; Meillon, Cyril; Bron, Alain Marie; Arnould, Louis; Creuzot-Garcher, Catherine
title: Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford–AstraZeneca COVID-19 vaccine
date: 2022-01-20
journal: Am J Ophthalmol Case Rep
DOI: 10.1016/j.ajoc.2022.101281
sha: 8e89ef4b062d07adb7909775b06206079dadec1d
doc_id: 714664
cord_uid: fvlh2gkf

PURPOSE: To report a case of bilateral acute macular neuroretinopathy following the first dose of Oxford-AstraZeneca COVID-19 (coronavirus disease 2019) vaccine in a young, Caucasian, and healthy woman. OBSERVATIONS: A 25-year-old Caucasian female patient presented to the ophthalmology department of Dijon University Hospital with a 3-week history of black spots and paracentral scotoma in both eyes. She had no past medical history and was using the combined estrogen-progestin oral contraceptive (COC). These symptoms occurred 24 h after receiving the first Oxford-AstraZeneca COVID-19 vaccination dose. The ophthalmologic signs were preceded a few hours earlier by fever and flu-like symptoms. Ophthalmologic examination revealed a preserved visual acuity with a quiet anterior segment and normal fundus in both eyes. Findings on multimodal retinal imaging, particularly near-infrared reflectance (NIR) and optical coherence tomography (OCT) imaging, were classical of an acute macular neuroretinopathy in both eyes. CONCLUSIONS: and importance: COVID-19 vaccination is justified as an essential public health measure. Acute macular neuroretinopathy may occur in patient receiving a COVID-19 vaccination dose. Further reports are needed to confirm this association. Physicians should be aware of this complication and request an eye examination with at least OCT or NIR imaging in the case of any visual symptoms after vaccination, notably in young women using COC.

Purpose: To report a case of bilateral acute macular neuroretinopathy following the first 2 dose of Oxford-AstraZeneca COVID-19 (coronavirus disease 2019) vaccine in a young, 3

Caucasian, and healthy woman. 4

Observations: A 25-year-old Caucasian female patient presented to the ophthalmology 5 department of Dijon University Hospital with a 3-week history of black spots and 6 paracentral scotoma in both eyes. She had no past medical history and was using the 7 combined estrogen-progestin oral contraceptive (COC). These symptoms occurred 24 h 8 after receiving the first Oxford-AstraZeneca COVID-19 vaccination dose. The 9

ophthalmologic signs were preceded a few hours earlier by fever and flu-like symptoms. 10

Ophthalmologic examination revealed a preserved visual acuity with a quiet anterior 11 segment and normal fundus in both eyes. Findings on multimodal retinal imaging, 12 particularly near-infrared reflectance (NIR) and optical coherence tomography (OCT) 13 imaging, were classical of an acute macular neuroretinopathy in both eyes. 14 Conclusions and importance: COVID-19 vaccination is justified as an essential public 15 health measure. Acute macular neuroretinopathy may occur in patient receiving a 16 COVID-19 vaccination dose. Further reports are needed to confirm this association. 17

Physicians should be aware of this complication and request an eye examination with at 18 least OCT or NIR imaging in the case of any visual symptoms after vaccination, notably 19 in young women using COC. 20

The Oxford-AstraZeneca coronavirus disease-2019 (COVID-19) vaccine, codenamed 2 "ChAdOx1 nCoV-19" or "AZD1222," is a chimpanzee adenoviral vectored vaccine with a 3 full-length severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike insert, 4 co-developed at the University of Oxford (Oxford, UK) and AstraZeneca (Cambridge, 5 UK). The interim analysis of ongoing clinical trials published to date showed that 6 AZD1222 has an acceptable safety profile and is efficacious against symptomatic 7 COVID-19. 1 The vaccine's local and systemic reactogenicity was well tolerated. The 8 side effects were less frequent and of lower intensity in older adults, with lower doses, 9

and after the second dose. 1 Ocular involvement after vaccination is rare and a few 10 week history of black spots and paracentral scotoma in both eyes. These symptoms 5 occurred 24 h after receiving the first vaccination dose. She did not describe any 6 change in her visual symptoms before our examination. The ophthalmologic signs were 7 preceded a few hours earlier by fever and flu-like symptoms that are common side 8 effects in young people after the AZD1222 vaccine. The patient had no past medical 9 history or allergy. She was using the combined estrogen-progestin oral contraceptive 10 (COC), was a non-smoker, and denied any recent illicit drug use. 

Caucasian women and is commonly associated with non-specific flu-like illness, fever, 3 or oral contraceptive use. 5-7 It can affect one or both eyes with symptoms ranging from 4 paracentral scotomas to impaired visual acuity. Fortunately, its prognosis is usually 5 favorable within weeks with an improvement of symptoms and lesions without any Recently, a few cases of a rare clotting disorder have been linked to AZD1222 and 19 described as vaccine-induced prothrombotic immune thrombocytopenia. 14,15 This seems 20 unlikely in our case, since the blood count (platelet count: 210,000 platelets/mL) and 21 coagulability profile were within normal. The onset of the first symptoms was 24 h after 22 the vaccination, whereas in VIPIT this occurs at least 4 days after vaccination. The patient's written consent for publication was obtained. 2

Due to its non-interventional character and retrospective design, the Medical Ethics 4

Committee of the Dijon University Hospital approved the use of this case report data. 5

None. 7

We declare no competing interests. 9

All authors provided care for the patient. PHG and FB drafted the manuscript. FB, LA, 11 IBG, CM, AMB and CCG provided supervision, discussion, and additional suggestions. 12

All authors attest that they meet the current ICMJE criteria for Authorship. 13

The authors thank Valerie Ducret for her precious help with this work. J o u r n a l P r e -p r o o f 

Safety and efficacy of the ChAdOx1 2 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 3 randomised controlled trials in Brazil, South Africa, and the UK. Lancet

Vaccination

Effect of SARS-CoV-2 mRNA vaccination on ocular 9 herpes simplex and varicella-zoster virus reactivation: should preventive antiviral 10 treatment be given in known herpes patients

Anterior 13 uveitis onset after bnt162b2 vaccination: is this just a coincidence?

Optical coherence tomography 16 diagnostic signs in posterior uveitis

Acute macular neuroretinopathy: A 19 comprehensive review of the literature

Paracentral acute middle maculopathy: a 22 new variant of acute macular neuroretinopathy associated with retinal capillary 23 ischemia

Acute macular neuroretinopathy 26 associated with influenza vaccination with decreased flow at the deep capillary plexus 27 on OCT angiography

Acute macular 30 neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination

Acute macular 36 neuroretinopathy following COVID-19 vaccination

Acute 39

Macular Neuroretinopathy following Coronavirus Disease 2019 Vaccination

Acute 42 macular neuroretinopathy: pathogenetic insights from optical coherence tomography 43 angiography